Skip to main content

Table 2 Univariate and multivariate analysis of HGS, clinical and pathologic factors in validation cohorts

From: A signature of hypoxia-related factors reveals functional dysregulation and robustly predicts clinical outcomes in stage I/II colorectal cancer patients

Characteristic CIT/GSE39582 CRC TCGA CRC Meta-validation
Univariate Multivariate Univariate Multivariate Univariate Multivariate
HR (95% CI) P-value HR (95%CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
HGS 8.66 (4.37–17.17) < 0.001 7.54 (3.78–15.06) < 0.001 2.59 (1.08–6.25) 0.04 2.59 (1.08–6.25) 0.04 8.25 (3.09–22.03) < 0.001 7.25 (2.72–19.29) < 0.001
Age 1.01 (0.99 –1.03) 0.58    1.01 (0.98–1.04) 0.37    0.97 (0.95–1.00) 0.02 0.98 (0.96–1.00) 0.05
Gender 1.53 (0.898–2.62) 0.12    1.56 (0.81–2.99) 0.18    0.68 (0.39–1.16) 0.15   
TNM stage 7.89 (1.11–55.91) < 0.001 5.76 (0.81–41.12) 0.08 1.83 (0.76–4.41) 0.17    3.99 (1.24–12.80) 0.01 3.73 (1.16–11.99) 0.03
Tumor location 1.08 (0.64–1.84) 0.78    1.09 (0.59–2.04) 0.78    1.30 (0.57–2.99) 0.53   
MMR status 1.63 (0.70–3.82) 0.25    0.64 (0.34–1.24) 0.18    1.27 (0.42–3.86) 0.67   
CIMP status 0.95 (0.44–2.02) 0.89        0.91 (0.32–2.55) 0.85   
CIN status 1.69 (0.75–3.81) 0.20           
TP53 mutation 1.39 (0.78–2.48) 0.27           
KRAS mutation 1.44 (0.86–2.40) 0.16    1.02 (0.23–4.60) 0.98    1.40 (0.50–3.94) 0.52   
BRAF mutation 1.42 (0.57–3.58) 0.45        1.72(0.61–4.81) 0.30